Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Danmark |
|---|---|
| Lista | Large Cap Copenhagen |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Valby, Denmark, 20 December 2023 - H. Lundbeck A/S (Lundbeck) hereby publishes and reports transactions made by executives and persons closely associated with them with shares and linked securities in Lundbeck.
+--+-----------------+--------------+---------------+
|1.|Details of the |
| |person |
| |discharging |
| |managerial |
| |responsibilities |
| |/ person closely |
| |associated |
+--+-----------------+--------------+---------------+
|a)|Name |Hossein Armandi |
+--+-----------------+--------------+---------------+
|2.|Reason for the |
| |notification |
+--+-----------------+--------------+---------------+
|a)|Position/status |Member of the board |
| | |of directors |
+--+-----------------+--------------+---------------+
|b)|Initial |Initial notification |
| |notification/Amen| |
| |dment | |
+--+-----------------+--------------+---------------+
|3.|Details of the |
| |issuer, |
| |emission |
| |allowance |
| |market |
| |participant, |
| |auction |
| |platform, |
| |auctioneer or |
| |auction monitor |
+--+-----------------+--------------+---------------+
|a)|Name |H. Lundbeck A/S |
+--+-----------------+--------------+---------------+
|b)|LEI code |5493006R4KC2OI5D3470 |
+--+-----------------+--------------+---------------+
|4 |Details of the |
| |transaction(s): |
| |section to be |
| |repeated for (i) |
| |each type of |
| |instrument; (ii) |
| |each type of |
| |transaction; |
| |(iii) each date; |
| |and (iv) each |
| |place where |
| |transactions |
| |have been |
| |conducted |
+--+-----------------+--------------+---------------+
|a)|Description of |SharesH. Lundbeck |
| |the financial |A/S, B-shares: |
| |instrument, type |DK0061804770 |
| |of instrument | |
| |Identification | |
| |code | |
+--+-----------------+--------------+---------------+
|b)|Nature of the |Sale of shares |
| |transaction | |
+--+-----------------+--------------+---------------+
|c)|Price(s) and |Price(s) |Volume(s) |
| |volume(s) | | |
+--+-----------------+--------------+---------------+
| | |DKK 32.34 (B|B-shares: 1,000|
| | |-shares) | |
+--+-----------------+--------------+---------------+
|d)|Aggregated | |
| |information | |
| |- Aggregated | |
| |volume | |
| |- Price | |
+--+-----------------+--------------+---------------+
|e)|Date of the |2023-12-20 |
| |transaction | |
+--+-----------------+--------------+---------------+
|f)|Place of the |NASDAQ Copenhagen |
| |transaction |XCSE |
+--+-----------------+--------------+---------------+Persons under an obligation to report are defined as members of the Executive Management, members of the Board of Directors and other executives of H. Lundbeck A/S and persons/entities closely associated to them.
Closely associated persons/entities means inter alia:
- spouse or cohabitant
- dependent children
- legal entities in which the executive has a controlling influence.
Lundbeck contacts
Investors: Media:
Palle Holm Olesen Thomas Mikkel
Mortensen
Vice President, Investor Relations Media Relations Lead,
Corporate
Communication
PALO@lundbeck.com THMR@lundbeck.com
+45 30 83 24 26 +45 30 83 30 24
About H. Lundbeck A/S
Lundbeck is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research. We are tirelessly dedicated to restoring brain health, so every person can be their best. We are committed to fighting stigma and discrimination against people living with brain diseases and advocating for broader social acceptance of people with brain health conditions. Our research programs tackle some of the most complex challenges in neuroscience, and our pipeline is focused on bringing forward transformative treatments for brain diseases for which there are few, if any therapeutic options.
For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us via LinkedIn.